Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab Phase 1 Study in Early Alzheimer's Disease
NCT02624778Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2015
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of donanemab in Alzheimer's disease (AD) (9 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr) at Week 72. Started Dec 2015; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02624778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624778.